Skip to main content
SpringerLink
Log in

Behandlung des fortgeschrittenen hormonsensitiven Prostatakarzinoms mittels Degarelix

Treatment of advanced hormone-sensitive prostate cancer using degarelix

  • Evidenzbasierte Medizin
  • Published:
Der Urologe Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Carter NJ, Keam SJ (2014) Degarelix: a review of its use in patients with prostate cancer. Drugs 74:699–712. https://doi.org/10.1007/s40265-014-0211-y

    Article  CAS  PubMed  Google Scholar 

  2. Cornford P, van den Bergh RCN, Briers E et al (2021) EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol 79:263–282. https://doi.org/10.1016/j.eururo.2020.09.046

    Article  CAS  PubMed  Google Scholar 

  3. Cui Y, Zong H, Yan H et al (2014) Degarelix versus goserelin plus bicalutamide therapy for lower urinary tract symptom relief, prostate volume reduction and quality of life improvement in men with prostate cancer: a systematic review and meta-analysis. Urol Int 93:152–159. https://doi.org/10.1159/000356272

    Article  CAS  PubMed  Google Scholar 

  4. George G, Garmo H, Scailteux L‑M et al (2021) Risk of cardiovascular disease following gonadotropin-releasing hormone agonists vs antagonists in prostate cancer: real-world evidence from five databases. Int J Cancer 148:2203–2211. https://doi.org/10.1002/ijc.33397

    Article  CAS  PubMed  Google Scholar 

  5. Klotz L, Miller K, Crawford ED et al (2014) Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists. Eur Urol 66:1101–1108. https://doi.org/10.1016/j.eururo.2013.12.063

    Article  CAS  PubMed  Google Scholar 

  6. Lopes RD, Higano CS, Slovin SF et al (2021) Cardiovascular safety of degarelix versus leuprolide in patients with prostate cancer: the primary results of the PRONOUNCE randomized trial. Circulation. https://doi.org/10.1161/CIRCULATIONAHA.121.056810

    Article  PubMed  Google Scholar 

  7. Lu L, Peters J, Roome C, Stein K (2012) Cost-effectiveness analysis of degarelix for advanced hormone-dependent prostate cancer. BJU Int 109:1183–1192. https://doi.org/10.1111/j.1464-410X.2011.10434.x

    Article  PubMed  Google Scholar 

  8. Sari Motlagh R, Abufaraj M, Mori K et al (2021) The efficacy and safety of relugolix compared with degarelix in advanced prostate cancer patients: a network meta-analysis of randomized trials. Eur Urol Oncol. https://doi.org/10.1016/j.euo.2021.07.002

    Article  PubMed  Google Scholar 

  9. Shore ND, Saad F, Cookson MS et al (2020) Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J Med 382:2187–2196. https://doi.org/10.1056/NEJMoa2004325

    Article  CAS  PubMed  Google Scholar 

  10. Zengerling F, Jakob JJ, Schmidt S et al (2021) Degarelix for treating advanced hormone-sensitive prostate cancer. Cochrane Database Syst Rev 8:CD12548. https://doi.org/10.1002/14651858.CD012548.pub2

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Urologische Klinik, Martha-Maria-Krankenhaus Nürnberg, Stadenstr. 58, 90491, Nürnberg, Deutschland

    Nikolaos Pyrgidis, Georgios Hatzichristodoulou &  Ioannis Sokolakis MSc FEBU FECSM

  2. UroEvidence@Deutsche Gesellschaft für Urologie, Berlin, Deutschland

    Ioannis Sokolakis MSc FEBU FECSM

Authors
  1. Nikolaos Pyrgidis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Georgios Hatzichristodoulou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ioannis Sokolakis MSc FEBU FECSM
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ioannis Sokolakis MSc FEBU FECSM.

Ethics declarations

Interessenkonflikt

N. Pyrgidis, G. Hatzichristodoulou und I. Sokolakis geben an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Additional information

Die Zusammenfassung ist eine Übersetzung des Abstracts der Originalpublikation

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pyrgidis, N., Hatzichristodoulou, G. & Sokolakis, I. Behandlung des fortgeschrittenen hormonsensitiven Prostatakarzinoms mittels Degarelix. Urologe 61, 63–67 (2022). https://doi.org/10.1007/s00120-021-01735-x

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-021-01735-x

Search

Navigation